These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11561179)

  • 41. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
    Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
    Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hyperlipidaemia and cardiovascular disease: statin update.
    Roberts AW; Salim M
    Curr Opin Lipidol; 2007 Jun; 18(3):381-3. PubMed ID: 17495613
    [No Abstract]   [Full Text] [Related]  

  • 43. Hyperlipidaemia and cardiovascular disease.
    Ansell BJ
    Curr Opin Lipidol; 2008 Aug; 19(4):433-4. PubMed ID: 18607193
    [No Abstract]   [Full Text] [Related]  

  • 44. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of simvastatin and pravastatin on endothelium-dependent relaxation in hypercholesterolemic rabbits.
    Jorge PA; Ozaki MR; Metze K
    Exp Toxicol Pathol; 1994 Dec; 46(6):465-9. PubMed ID: 7703678
    [TBL] [Abstract][Full Text] [Related]  

  • 46. American Heart Association--scientific sessions 2004. Drug highlights I. 7-10 November 2004, New Orleans, LA, USA.
    Dalziel C
    IDrugs; 2004 Dec; 7(12):1085-7. PubMed ID: 15599799
    [No Abstract]   [Full Text] [Related]  

  • 47. Effect of cholesterol-lowering therapy on endothelial function.
    Houghton JL
    Circulation; 2001 Jul; 104(2):E6. PubMed ID: 11447096
    [No Abstract]   [Full Text] [Related]  

  • 48. Cholesterol lowering: perspectives on the 4S and West of Scotland studies.
    Olin JW
    Cleve Clin J Med; 1996; 63(2):80-3. PubMed ID: 8819689
    [No Abstract]   [Full Text] [Related]  

  • 49. [The other face of statins].
    Kaletha K; Chodorowski Z; Sein Anand J; Szydłowska M; Rybakowska I; Nagel-Starczynowska G
    Przegl Lek; 2002; 59(4-5):364-6. PubMed ID: 12184008
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lipid-lowering treatment patterns in patients with new cardiovascular events - estimates from population-based register data in Sweden.
    Hallberg S; Banefelt J; Fox KM; Mesterton J; Johansson G; Levin LÅ; Sobocki P; Gandra SR
    Int J Clin Pract; 2016 Mar; 70(3):222-8. PubMed ID: 26799539
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism.
    Lang JE; Wang P; Glueck CJ
    Clin Chim Acta; 1996 Oct; 254(1):65-92. PubMed ID: 8894313
    [No Abstract]   [Full Text] [Related]  

  • 52. Ezetimibe/simvastatin (INEGY) in the treatment of hyperlipidaemia.
    Kastelein JJ; Sankatsing RR
    Int J Clin Pract; 2005 Dec; 59(12):1464-71. PubMed ID: 16351680
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Statins prevent coronary heart disease.
    Oliver MF
    Lancet; 1995 Nov; 346(8987):1378-9. PubMed ID: 7475814
    [No Abstract]   [Full Text] [Related]  

  • 54. Simvastatin: two decades in a circle.
    Kolovou GD; Katerina A; Ioannis V; Cokkinos DV
    Cardiovasc Ther; 2008; 26(2):166-78. PubMed ID: 18485137
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Statins and coronary heart disease.
    Oliver MF
    Lancet; 1996 Jul; 348(9019):57. PubMed ID: 8691943
    [No Abstract]   [Full Text] [Related]  

  • 56. Smoking diminishes the beneficial effect of statins: observations from the landmark trials.
    Milionis HJ; Rizos E; Mikhailidis DP
    Angiology; 2001 Sep; 52(9):575-87. PubMed ID: 11570656
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease.
    Lefer AM; Scalia R; Lefer DJ
    Cardiovasc Res; 2001 Feb; 49(2):281-7. PubMed ID: 11164838
    [No Abstract]   [Full Text] [Related]  

  • 58. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome.
    Rabelink AJ; Hené RJ; Erkelens DW; Joles JA; Koomans HA
    Lancet; 1988 Dec; 2(8624):1335-8. PubMed ID: 2904053
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Statin is indicated to all patients with high risk of complications of coronary heart disease irrespective of the level of low density lipoprotein cholesterol. Results of HPS].
    Gratsianskiĭ NA
    Kardiologiia; 2002; 42(2):84-5. PubMed ID: 12494213
    [No Abstract]   [Full Text] [Related]  

  • 60. Simvastatin and pravastatin equally improve flow-mediated dilation in males with hypercholesterolemia.
    Sebestjen M; Boh M; Keber I
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):999-1003. PubMed ID: 12635468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.